Analysts Are Bullish on Top Healthcare Stocks: Third Harmonic Bio, Inc. (THRD), Treace Medical Concepts (TMCI)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Third Harmonic Bio, Inc. (THRD – Research Report), Treace Medical Concepts (TMCI – Research Report) and Lineage Therap (LCTX – Research Report) with bullish sentiments.

Third Harmonic Bio, Inc. (THRD)

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Third Harmonic Bio, Inc. yesterday. The company’s shares closed last Thursday at $5.97, close to its 52-week low of $3.75.

According to TipRanks.com, Slutsky is a 2-star analyst with an average return of -0.2% and a 38.8% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as ALX Oncology Holdings, Olema Pharmaceuticals, and Enliven Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Third Harmonic Bio, Inc..

See the top stocks recommended by analysts >>

Treace Medical Concepts (TMCI)

In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on Treace Medical Concepts, with a price target of $17.00. The company’s shares closed last Thursday at $10.00, close to its 52-week low of $9.23.

According to TipRanks.com, Zimmerman is a 4-star analyst with an average return of 3.5% and a 40.0% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Zimmer Biomet Holdings, and Organogenesis Holdings.

Treace Medical Concepts has an analyst consensus of Strong Buy, with a price target consensus of $19.33.

Lineage Therap (LCTX)

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Lineage Therap yesterday and set a price target of $4.00. The company’s shares closed last Thursday at $1.07, close to its 52-week low of $1.00.

According to TipRanks.com, Mamtani is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -24.6% and a 22.4% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Checkpoint Therapeutics.

Currently, the analyst consensus on Lineage Therap is a Strong Buy with an average price target of $5.25.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on THRD:

• Third Harmonic Bio Announces Third Quarter 2023 Financial Results
• Third Harmonic Bio Announces Leadership Changes
• Third Harmonic Bio announces CSO Ray’s transition to SA, CFO Ho to depart
• Fourteen new option listings and three option delistings on October 18th
• Third Harmonic Bio files $400M mixed securities shelf